From Acute to Chronic: Why We Need to Develop Product Strategies for Tomorrow's Patients

Posted by Malik Kaman on Nov 22, 2016 12:50:59 PM

Despite the dramatic number of unmet needs that still exist across many tumor types, we have made significant progress in treating some cancers. Since the early 2000s, novel treatment options have fundamentally changed survival rates in chronic myeloid leukemia, metastatic melanoma, HER2+ breast cancer, chronic lymphocytic leukemia and many others. These advancements mark an important and growing trend in the cancer treatment landscape: a shift from acute to chronic treatments. 

Read More